TRPV2 and triple-negative breast carcinoma: A higher recurrence-free survival was associated with greater expression of TRPV2 in triple-negative breast cancer (TNBC) and estrogen receptor β- (ERβ-) negative breast cancer patients who underwent a chemotherapy regimen with doxorubicin [44].